<DOC>
	<DOCNO>NCT00180531</DOCNO>
	<brief_summary>The objective study evaluate prevalence sustain ventricular supraventricular rhythm disorder patient implanted CONTAK RENEWAL TR2 ventricular resynchronization therapy ( CRT ) device</brief_summary>
	<brief_title>Monitoring Arrhythmias HRV Patients With Heart Failure Treated With CRT Pacemaker Renewal TR2</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Moderate severe chronic heart failure , define presence NYHA class III IV symptom , Intra/interventricular synchronization disorder evaluate echocardiography and/or Doppler Tissue Imaging ( DTI , Yu 's method22 ) , Ejection fraction ( EF ) ≤ 40 % , If previous history myocardial infarction , MI must &gt; 60 day date inclusion , Estimated life expectancy &gt; 6 month case concomitant disease , Age ≥ 18 year , Optimal drug treatment chronic heart failure ( accord SFC* recommendation ) . Conventional indication treatment implantable defibrillator upon inclusion , Cardiac transplant envisage within 6 month , Unexplained syncope , MI &lt; 60 day inclusion , Non compliance drug treatment chronic heart failure , Any coronary pathology may treat revascularisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>